Luis Fernando
López Cortés
Publicaciones en las que colabora con Luis Fernando López Cortés (19)
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2014
-
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV
The Lancet Infectious Diseases
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients
PLoS ONE, Vol. 9, Núm. 7
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients
Hepatology, Vol. 56, Núm. 4, pp. 1261-1270
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2009
-
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
Hepatology, Vol. 50, Núm. 4, pp. 1056-1063
-
Natural history of compensated hepatitis c virusrelated cirrhosis in HIV-infected patients
Clinical Infectious Diseases, Vol. 49, Núm. 8, pp. 1274-1282
2008
-
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
AIDS, Vol. 22, Núm. 8, pp. 923-930
-
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796
-
Role of pegylated interferon-α-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients
Clinical Pharmacology and Therapeutics, Vol. 84, Núm. 5, pp. 573-580
2007
-
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354
-
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235
-
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529
2006
-
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846